Clinical Uses of Intravenous Immunoglobulin

Overview

Journal Clin Exp Immunol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2005 Sep 24

PMID 16178850

Citations 129

Authors

S Jolles

W A C Sewell

S A Misbah

Affiliations

Soon will be listed here.

Citing Articles

Sepsis: the evolution of molecular pathogenesis concepts and clinical management.

Feng Z, Wang L, Yang J, Li T, Liao X, Kang Y MedComm (2020). 2025; 6(3):e70109.

PMID: 39991626 PMC: 11847631. DOI: 10.1002/mco2.70109.

Autoantibodies in COVID-19: implications for disease severity and clinical outcomes.

Galipeau Y, Cooper C, Langlois M Front Immunol. 2025; 15():1509289.

PMID: 39835117 PMC: 11743527. DOI: 10.3389/fimmu.2024.1509289.

Induced B-Cell Receptor Diversity Predicts PD-1 Blockade Immunotherapy Response.

Che Y, Lee J, Abou-Taleb F, Rieger K, Satpathy A, Chang A bioRxiv. 2024; .

PMID: 39677742 PMC: 11643026. DOI: 10.1101/2024.12.03.626669.

Intravenous immunoglobulin‑based adjuvant therapy for severe fever with thrombocytopenia syndrome: A single‑center retrospective cohort study.

Zhai Y, Li H, Xia P, Jiang Y, Tong H, Zhou D J Med Virol. 2024; 96(11):e70017.

PMID: 39494463 PMC: 11600480. DOI: 10.1002/jmv.70017.

The Emerging Role of Immunoglobulins and Complement in the Stimulation of Neuronal Activity and Repair: Not as Simple as We Thought.

Veremeyko T, Barteneva N, Vorobyev I, Ponomarev E Biomolecules. 2024; 14(10).

PMID: 39456256 PMC: 11506258. DOI: 10.3390/biom14101323.

References

Marchalonis J, Kaymaz H, Dedeoglu F, Schluter S, Yocum D, EDMUNDSON A . Human autoantibodies reactive with synthetic autoantigens from T-cell receptor beta chain. Proc Natl Acad Sci U S A. 1992; 89(8):3325-9. PMC: 48859. DOI: 10.1073/pnas.89.8.3325. View

van Schaik I, Lundkvist I, Vermeulen M, Brand A . Polyvalent immunoglobulin for intravenous use interferes with cell proliferation in vitro. J Clin Immunol. 1992; 12(5):325-34. DOI: 10.1007/BF00920789. View

Takei S, Arora Y, Walker S . Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens [see comment]. J Clin Invest. 1993; 91(2):602-7. PMC: 287991. DOI: 10.1172/JCI116240. View

Vassilev T, Gelin C, Kaveri S, Zilber M, Boumsell L, Kazatchkine M . Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVIg). Clin Exp Immunol. 1993; 92(3):369-72. PMC: 1554769. DOI: 10.1111/j.1365-2249.1993.tb03407.x. View

Andersson U, Bjork L, Andersson J . Down-regulation of cytokine production and interleukin-2 receptor expression by pooled human IgG. Immunology. 1993; 79(2):211-6. PMC: 1421866. View

Lam L, Whitsett C, McNicholl J, Hodge T, Hooper J . Immunologically active proteins in intravenous immunoglobulin. Lancet. 1993; 342(8872):678. DOI: 10.1016/0140-6736(93)91784-j. View

Klaesson S, Ringden O, Markling L, Remberger M, Lundkvist I . Immune modulatory effects of immunoglobulins on cell-mediated immune responses in vitro. Scand J Immunol. 1993; 38(5):477-84. DOI: 10.1111/j.1365-3083.1993.tb02591.x. View

Ling Z, Yeoh E, Webb B, Farrell K, Doucette J, Matheson D . Intravenous immunoglobulin induces interferon-gamma and interleukin-6 in vivo. J Clin Immunol. 1993; 13(5):302-9. DOI: 10.1007/BF00920238. View

Dalakas M, Illa I, Dambrosia J, Soueidan S, Stein D, Otero C . A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993; 329(27):1993-2000. DOI: 10.1056/NEJM199312303292704. View

10.

Gamm H, Huber C, Chapel H, Lee M, Ries F, Dicato M . Intravenous immune globulin in chronic lymphocytic leukaemia. Clin Exp Immunol. 1994; 97 Suppl 1:17-20. PMC: 1550375. View

11.

Campione E, Marulli G, Carrozzo A, Chimenti M, Costanzo A, Bianchi L . High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis. Acta Derm Venereol. 2003; 83(6):430-2. DOI: 10.1080/0001550310005852. View

12.

Jolles S, Sewell C, Webster D, Ryan A, Heelan B, Waite A . Adjunctive high-dose intravenous immunoglobulin treatment for resistant atopic dermatitis: efficacy and effects on intracellular cytokine levels and CD4 counts. Acta Derm Venereol. 2003; 83(6):433-7. DOI: 10.1080/00015550310020549. View

13.

van Koningsveld R, Schmitz P, Meche F, Visser L, Meulstee J, van Doorn P . Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet. 2004; 363(9404):192-6. DOI: 10.1016/s0140-6736(03)15324-x. View

14.

Kumar N, Rodriguez M . Scleromyxedema in a patient with multiple sclerosis and monoclonal gammopathy on interferon beta-1a. Mult Scler. 2004; 10(1):85-6. DOI: 10.1191/1352458504ms987cr. View

15.

Ohlsson A, Lacy J . Intravenous immunoglobulin for preventing infection in preterm and/or low-birth-weight infants. Cochrane Database Syst Rev. 2004; (1):CD000361. DOI: 10.1002/14651858.CD000361.pub2. View

16.

Ohlsson A, Lacy J . Intravenous immunoglobulin for suspected or subsequently proven infection in neonates. Cochrane Database Syst Rev. 2004; (1):CD001239. DOI: 10.1002/14651858.CD001239.pub2. View

17.

Hughes R, Raphael J, Swan A, Doorn P . Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev. 2004; (1):CD002063. DOI: 10.1002/14651858.CD002063.pub2. View

18.

Bierling P, Godeau B . Intravenous immunoglobulin and autoimmune thrombocytopenic purpura: 22 years on. Vox Sang. 2004; 86(1):8-14. DOI: 10.1111/j.0042-9007.2004.00391.x. View

19.

Aghamohammadi A, Moin M, Farhoudi A, Rezaei N, Pourpak Z, Movahedi M . Efficacy of intravenous immunoglobulin on the prevention of pneumonia in patients with agammaglobulinemia. FEMS Immunol Med Microbiol. 2004; 40(2):113-8. DOI: 10.1016/S0928-8244(03)00304-3. View

20.

Ameratunga R, Sinclair J, Kolbe J . Increased risk of adverse events when changing intravenous immunoglobulin preparations. Clin Exp Immunol. 2004; 136(1):111-3. PMC: 1809000. DOI: 10.1111/j.1365-2249.2004.02412.x. View